References in periodicals archive ?
The design of a multiple drug combination for treating stage 4 bladder cancer depends on a strategy of inhibiting the highly expressed genes ADRM1, COPS5, PSMD8, SUMO2, RNF126, CALR, PDIA3, DNAJB11, HSPA5, RPN1, HSP90AA1, HSPA1B, METTL23, RARRES3, KPNA2, PSMD12, ECT2, JUN, TK1, TUBA1C, HN1, and ENO1; activating the suppressed genes BCL3, FOS, UBC, and GTF2A1; and suppressing the drug's effect on the nondifferentially expressed genes, which are the same as those in stage 1 bladder cancer.
The bold proteins, including RARRES3, TUBA1C, PSMD8, HSPA1B, RPS20, CALR, PAAF1, and KPNA2, were the identified core network biomarkers.
The bold proteins RARRES3, TUBA1C, PSMD8, HSPA1B, RPS20, CALR, PAAF1, and KPNA2 were the identified core network biomarkers.
Deoxyribonucleicacid was isolated from the blood of both groups, and polymorphisms of the HSPA1B gene (NM_005346.
1059Ggreater than A polymorphic point of the HSPA1B gene or between the A allele of the cases and controls (pgreater than 0.
Medical browser ?
Full browser ?
- HSP90 beta
- Hsp90 heat-shock proteins
- HSPA Evolved
- HSPB (heat shock 27kD) associated protein 1
- HSPB (heat shock 27kDa) associated protein 1
- HSPB1-associated protein 1